JPWO2022189807A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022189807A5 JPWO2022189807A5 JP2023555335A JP2023555335A JPWO2022189807A5 JP WO2022189807 A5 JPWO2022189807 A5 JP WO2022189807A5 JP 2023555335 A JP2023555335 A JP 2023555335A JP 2023555335 A JP2023555335 A JP 2023555335A JP WO2022189807 A5 JPWO2022189807 A5 JP WO2022189807A5
- Authority
- JP
- Japan
- Prior art keywords
- clostridial neurotoxin
- modified clostridial
- modified
- domain
- modification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010055044 Tetanus Toxin Proteins 0.000 claims 68
- 238000012986 modification Methods 0.000 claims 35
- 230000004048 modification Effects 0.000 claims 35
- 150000007523 nucleic acids Chemical class 0.000 claims 21
- 108020004707 nucleic acids Proteins 0.000 claims 20
- 102000039446 nucleic acids Human genes 0.000 claims 20
- 125000000539 amino acid group Chemical group 0.000 claims 18
- 108030001720 Bontoxilysin Proteins 0.000 claims 17
- 230000003647 oxidation Effects 0.000 claims 15
- 238000007254 oxidation reaction Methods 0.000 claims 15
- 238000000034 method Methods 0.000 claims 11
- 150000001413 amino acids Chemical group 0.000 claims 10
- 208000008238 Muscle Spasticity Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 208000018198 spasticity Diseases 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 8
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 claims 7
- 239000002537 cosmetic Substances 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 208000007101 Muscle Cramp Diseases 0.000 claims 6
- 230000002378 acidificating effect Effects 0.000 claims 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 5
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims 5
- 229930182817 methionine Natural products 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000014094 Dystonic disease Diseases 0.000 claims 4
- 206010040954 Skin wrinkling Diseases 0.000 claims 4
- 208000005392 Spasm Diseases 0.000 claims 4
- 208000004350 Strabismus Diseases 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 230000028327 secretion Effects 0.000 claims 4
- 230000002194 synthesizing effect Effects 0.000 claims 4
- 206010002153 Anal fissure Diseases 0.000 claims 2
- 208000016583 Anus disease Diseases 0.000 claims 2
- 208000019505 Deglutition disease Diseases 0.000 claims 2
- 208000000289 Esophageal Achalasia Diseases 0.000 claims 2
- 208000001692 Esotropia Diseases 0.000 claims 2
- 208000029728 Eyelid disease Diseases 0.000 claims 2
- 206010063006 Facial spasm Diseases 0.000 claims 2
- 208000009531 Fissure in Ano Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 208000004095 Hemifacial Spasm Diseases 0.000 claims 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 2
- 206010023644 Lacrimation increased Diseases 0.000 claims 2
- 208000029578 Muscle disease Diseases 0.000 claims 2
- 208000021642 Muscular disease Diseases 0.000 claims 2
- 208000000112 Myalgia Diseases 0.000 claims 2
- 208000002033 Myoclonus Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000007920 Neurogenic Inflammation Diseases 0.000 claims 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 2
- 206010029279 Neurogenic bladder Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 206010030136 Oesophageal achalasia Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000036496 Pelvic floor dyssynergia Diseases 0.000 claims 2
- 206010039424 Salivary hypersecretion Diseases 0.000 claims 2
- 201000010829 Spina bifida Diseases 0.000 claims 2
- 208000006097 Spinal Dysraphism Diseases 0.000 claims 2
- 208000003028 Stuttering Diseases 0.000 claims 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 2
- 206010043269 Tension headache Diseases 0.000 claims 2
- 208000008548 Tension-Type Headache Diseases 0.000 claims 2
- 206010044074 Torticollis Diseases 0.000 claims 2
- 206010044565 Tremor Diseases 0.000 claims 2
- 208000016599 Uterine disease Diseases 0.000 claims 2
- 208000018839 Wilson disease Diseases 0.000 claims 2
- 208000013142 Writer cramp Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 201000000621 achalasia Diseases 0.000 claims 2
- 201000002898 anismus Diseases 0.000 claims 2
- 206010005159 blepharospasm Diseases 0.000 claims 2
- 230000000744 blepharospasm Effects 0.000 claims 2
- 206010006514 bruxism Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010008129 cerebral palsy Diseases 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000010118 dystonia Diseases 0.000 claims 2
- 201000002865 focal hand dystonia Diseases 0.000 claims 2
- 210000001061 forehead Anatomy 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 208000018197 inherited torticollis Diseases 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 230000004317 lacrimation Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000013465 muscle pain Diseases 0.000 claims 2
- 208000018360 neuromuscular disease Diseases 0.000 claims 2
- 230000001590 oxidative effect Effects 0.000 claims 2
- 208000026451 salivation Diseases 0.000 claims 2
- 210000002460 smooth muscle Anatomy 0.000 claims 2
- 230000001148 spastic effect Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 241001112695 Clostridiales Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 241000223503 Platysma Species 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 206010040925 Skin striae Diseases 0.000 claims 1
- 208000031439 Striae Distensae Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 239000002581 neurotoxin Substances 0.000 claims 1
- 231100000618 neurotoxin Toxicity 0.000 claims 1
- 230000004433 ocular motility Effects 0.000 claims 1
- 230000003565 oculomotor Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2103372.5 | 2021-03-11 | ||
| GBGB2103372.5A GB202103372D0 (en) | 2021-03-11 | 2021-03-11 | Modified clostridial neurotoxins |
| PCT/GB2022/050641 WO2022189807A2 (en) | 2021-03-11 | 2022-03-11 | Modified clostridial neurotoxins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024512397A JP2024512397A (ja) | 2024-03-19 |
| JPWO2022189807A5 true JPWO2022189807A5 (https=) | 2025-03-17 |
| JP2024512397A5 JP2024512397A5 (https=) | 2025-03-17 |
Family
ID=75623101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023555335A Pending JP2024512397A (ja) | 2021-03-11 | 2022-03-11 | 改変クロストリジウム神経毒 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240327472A1 (https=) |
| EP (1) | EP4305050A2 (https=) |
| JP (1) | JP2024512397A (https=) |
| CN (1) | CN117222659A (https=) |
| AU (1) | AU2022234881A1 (https=) |
| GB (1) | GB202103372D0 (https=) |
| WO (1) | WO2022189807A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202214229D0 (en) * | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
| GB202214232D0 (en) * | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
| CH720447A2 (de) * | 2023-01-20 | 2024-07-31 | Abbvie Inc | Zusammensetzungen von clostridium botulinum neurotoxin serotyp a |
| CH720444A2 (de) | 2023-01-20 | 2024-07-31 | Abbvie Inc | Clostridium botulinum serotyp a neurotoxin (bont/a)- sequenzvarianten |
| CN119708179B (zh) * | 2024-12-19 | 2025-11-28 | 兰州大学 | A型肉毒毒素突变体及其应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| EP1099445A3 (en) | 1993-06-10 | 2001-09-05 | Allergan, Inc. | Treatment of neuromuscular disorders and conditions with different botulinum serotype |
| US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
| US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
| US20040126396A1 (en) | 1993-12-28 | 2004-07-01 | Allergan, Inc. | Botulinum toxin treatment for strabismus |
| US5670484A (en) | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
| US5714469A (en) | 1994-09-01 | 1998-02-03 | Smithkline Beecham Corporation | Method of treating sepsis |
| US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| US6767544B2 (en) | 2002-04-01 | 2004-07-27 | Allergan, Inc. | Methods for treating cardiovascular diseases with botulinum toxin |
| US6358917B1 (en) | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
| HK1046020B (en) | 1999-08-25 | 2007-05-11 | Allergan, Inc. | Activatable recombinant neurotoxins |
| GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US6265379B1 (en) | 1999-10-13 | 2001-07-24 | Allergan Sales, Inc. | Method for treating otic disorders |
| US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
| US6337075B1 (en) | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
| US6143306A (en) | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
| US6261572B1 (en) | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
| US6641820B1 (en) | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
| US6524580B1 (en) | 2000-02-15 | 2003-02-25 | Allergan Sales, Inc. | Method for treating thyroid disorders |
| US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
| US6299893B1 (en) | 2000-04-17 | 2001-10-09 | Marvin Schwartz | Method to reduce hair loss and stimulate hair regrowth |
| US6565870B1 (en) | 2000-04-28 | 2003-05-20 | Allergan, Inc. | Methods for treating bone tumors |
| US6306403B1 (en) | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
| US6903187B1 (en) | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
| US6423319B1 (en) | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
| US6827931B1 (en) | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
| US7273722B2 (en) | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
| US6623742B2 (en) | 2001-09-17 | 2003-09-23 | Allergan, Inc. | Methods for treating fibromyalgia |
| US7255866B2 (en) | 2001-09-17 | 2007-08-14 | Allergan, Inc. | Botulinum toxin therapy for fibromyalgia |
| US6921538B2 (en) | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
| JP2006513994A (ja) | 2002-10-15 | 2006-04-27 | アラーガン、インコーポレイテッド | ボツリヌス毒素歯科治療および歯科措置 |
| US7238357B2 (en) | 2002-11-05 | 2007-07-03 | Allergan, Inc. | Methods for treating ulcers and gastroesophageal reflux disease |
| US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
| US6838434B2 (en) | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
| US7220422B2 (en) | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
| US20040253274A1 (en) | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
| ES2369558T3 (es) | 2005-09-19 | 2011-12-01 | Allergan, Inc. | Toxinas clostridiales y toxinas clostridiales activables. |
| EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| WO2009015840A2 (en) * | 2007-07-27 | 2009-02-05 | Merz Pharma Gmbh & Co. Kgaa | Polypeptide for targeting of neural cells |
| GB0903006D0 (en) | 2009-02-23 | 2009-04-08 | Syntaxin Ltd | Modified non-cytotoxic proteases |
| CA2758274C (en) | 2009-04-14 | 2018-04-10 | Mcw Research Foundation, Inc. | Engineered botulinum neurotoxin |
| US8853360B2 (en) | 2010-06-23 | 2014-10-07 | Wisconsin Alumni Research Foundation | Engineered botulinum neurotoxin C1 with selective substrate specificity |
| WO2014079495A1 (en) | 2012-11-21 | 2014-05-30 | Syntaxin Limited | Methods for the manufacture of proteolytically processed polypeptides |
| GB201312317D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| EP3481852B1 (en) * | 2016-07-08 | 2022-12-07 | Children's Medical Center Corporation | A novel botulinum neurotoxin and its derivatives |
| EP3335719A1 (en) * | 2016-12-14 | 2018-06-20 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with a stabilized light chain |
| GB201815817D0 (en) | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
-
2021
- 2021-03-11 GB GBGB2103372.5A patent/GB202103372D0/en not_active Ceased
-
2022
- 2022-03-11 JP JP2023555335A patent/JP2024512397A/ja active Pending
- 2022-03-11 EP EP22712024.3A patent/EP4305050A2/en active Pending
- 2022-03-11 AU AU2022234881A patent/AU2022234881A1/en not_active Abandoned
- 2022-03-11 CN CN202280020283.9A patent/CN117222659A/zh active Pending
- 2022-03-11 WO PCT/GB2022/050641 patent/WO2022189807A2/en not_active Ceased
- 2022-03-11 US US18/549,871 patent/US20240327472A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528042A5 (https=) | ||
| JP2024012421A5 (https=) | ||
| AR132701A2 (es) | Neurotoxinas catiónicas | |
| AR108689A1 (es) | Neurotoxinas clostridiales quiméricas | |
| JP2019523015A5 (https=) | ||
| JP2015519362A5 (https=) | ||
| Dutton et al. | Botulinum toxin in ophthalmology | |
| Blitzer et al. | Botulinum toxin: basic science and clinical uses in otolaryngology | |
| JP2016513082A5 (https=) | ||
| EP4289868A1 (en) | Modified neurotoxin single-chain polypeptide and use thereof | |
| JP2005517627A5 (https=) | ||
| RU2015124069A (ru) | Способы производства протеолитически процессированных полипептидов | |
| CN103228286A (zh) | 可降解梭菌毒素 | |
| EP1994048A2 (de) | Pegyliertes mutiertes clostridium botulinum toxin | |
| JPWO2022189807A5 (https=) | ||
| WO2018233813A1 (en) | Novel recombinant botulinum toxin with increased duration of effect | |
| RU2023125799A (ru) | Модифицированные клостридиальные нейротоксины | |
| US11453903B2 (en) | Production of activated clostridial neurotoxins | |
| WO2012134902A1 (en) | Endopeptidase and neurotoxin combination treatment of dystonia, cerebral palsy and migraine | |
| JP2023090955A5 (https=) | ||
| CN112739320A (zh) | 肉毒杆菌神经毒素血清型e的治疗和美容用途 | |
| RU2023125554A (ru) | Клостридиальные нейротоксины, содержащие экзогенную петлю активации | |
| NZ747619B2 (en) | Chimeric neurotoxins | |
| RU2021111910A (ru) | Терапевтическое и косметическое применение нейротоксина ботулина серотипа e | |
| Keir | Botulinum toxin—physiology and applications in head and neck disorders |